Public area - News, events, announcments - Topic started by UK CAB Moderator - April 30 2008, 08:11 am

Title: Better antibiotics for second-line PCP treatment
Post by: UK CAB Moderator on April 30 2008, 08:11 am
PCP pneumonia is still a serious and present condition, especially for people diagnosed late with HIV. There is limited research on second-line treatments.

AIDSmeds reports on a systematic review of second-line therapy PCP studies:

Better Antibiotics for Second-Line PCP Treatment - AIDSmeds

Original abstract in the Journal of Acquired Immune Deficiency Syndromes, May 1 2008 edition:

Second-Line Salvage Treatment of AIDS-Associated Pneumocystis jirovecii Pneumonia: A Case Series and Systematic Review - JAIDS

29 studies, including 82 individual cases, yielded a total of 468 PCP second-line treatment episodes for review.

Response rates to second-line treatment were comparable for trimethoprim-sulfamethoxazole (Septrin, TMP-SMX) at 68%, and clindamycin-primaquine at 73%. Odds ratios for a successful response were: TMP-SMX - 2.1 (95% confidence interval: 1.1 to 3.2), clindamycin-primaquine - 2.7 (95% confidence interval: 1.3 to 4.0). The response rate for intravenous pentamidine was lower at 44%, odds ratio 0.8 (95% confidence interval: 0.6 to 1.0).

The authors conclude: "Clindamycin-primaquine is an alternative to intravenous pentamidine as second-line treatment for PCP in patients who fail treatment with TMP-SMX. TMP-SMX should be used as a second-line treatment for those failing first-line treatments with regimens other than TMP-SMX."

Systematic reviews have limitations (comparing samples, retrospective, non-randomised). This said, the round-up of outcomes from second-line clindamycin-primaquine is useful. The authors' recommendation on TMP-SMX as a second-line agent may be a cause of dismay to people allergic to this drug.

Ref: Benfield, Thomas et al. JAIDS Journal of Acquired Immune Deficiency Syndromes. 48(1):63-67, May 1, 2008.